 MEI Pharma Inc NASDAQ: MEIP and Kyowa Kirin Co Ltd have announced data from the pivotal Phase 2 TIDAL study of zandelisib as a single agent for follicular lymphoma FL patients who received at least two prior systemic therapies. Data demonstrated a 70.3 objective response rate ORR as determined by Independent Review Committee IRC assessment in the primary efficacy population n91. 